SIRT4 inhibits B‐cell lymphoma proliferation by inhibiting mitochondrial glutamine metabolism52; in addition to this, SIRT4 inhibits B‐cell lymphoma proliferation by inhibiting glutamine metabolism from suppressing the malignant biological behavior of thyroid cancer cells53; In conclusion, these findings suggest the potential of SIRT4 for tumor‐targeted therapeutic aspects, especially its potential to synergize with glutamine metabolism inhibitors for cancer treatment. This evidence concerns the gene SIRT4 and thyroid gland carcinoma.